Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
IN8BIO, INC.Bullish
IN8BIO는 2026년 2분기(6월 30일 마감) 기준 478만 달러의 영업손실과 987만 달러의 상반기 누적 영업손실을 기록했습니다. 2026년 6월 30일 기준 현금 보유액은 1,796만 달러로, 전년 말 2,709만 달러 대비 감소했습니다.…more
IN8BIO, INC.
IN8bio는 2026년 2분기 실적을 발표하며 480만 달러의 순손실(주당 0.25달러)을 기록했습니다. 주요 파이프라인인 DeltEx DRI의 임상 데이터가 긍정적으로 도출되었으며, 하반기 중 INB-619의 초기 생체 내 데이터 발표와 FDA 규제 경로 논의를 앞두고 있습니다.…more
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
IN8bio Grants Stock Options to New Employee
IN8bio announced the grant of stock options for 60,000 shares to a new employee under Nasdaq listing rules. This is a standard compensation practice for talent acquisition and has no material impact on the company's valuation.…more
●●●●●●●● ●●●●● ●●●●●●
IN8bio announced its participation in the upcoming Sidoti Small-Cap Virtual Conference to showcase its gamma-delta T cell platform and clinical pipeline. As this event is a standard investor presentation without new material business developments, the impact on the stock is expected to be neutral.…more
●●●●●●●● ●●●●● ●●●●●●
Clinical-stage biopharmaceutical company IN8bio announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. This event involves a fireside chat and investor meetings, which are standard corporate activities without immediate financial impact.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.